Developer docs
API playgroundTry for free, no card

Search company profiles

Bioplus Co.

Full company profile

uuid000bpvp

Namestring
Bioplus Co.
Legal namestring
BioPlus Co., Ltd.
Websiteurl
ubioplus.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

BioPlus Co., Ltd. is a South Korea-based biomedical device and biopharmaceutical company founded in 2003 and listed on KOSDAQ (ticker 099430) since September 2021. The company specializes in hyaluronic acid (HA)-based products built on its proprietary MDM® Technology platform, which combines Micro Bead Monophasic Technology (MBMT), Divinyl sulfone Multi-Crosslink Technology (DMCT), and Multiple Degree Amphiphilic Purification (MDAP). BioPlus is the only company globally using DVS rather than BDDE as the cross-linking agent for HA dermal fillers, supporting a premium positioning with products priced approximately 5x above competitors and generating a 48.7% operating margin in 2021.

The company's product portfolio spans three categories: (1) MDM® Filler products including SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, and IPCHE for aesthetic applications; (2) Medical devices including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), and Blad-Care (cystitis treatment); and (3) Cosmeceutical/mesotherapy products under the Kiara and Labella brands. BioPlus derives approximately 85% of revenue from HA fillers and serves medical aesthetic clinics, hospitals, and orthopedic/surgical providers across Korea, China, the U.S., Europe, the Middle East, South Asia, Latin America, and Southeast Asia.

BioPlus operates a sales-led go-to-market with premium pricing, combining direct sales to medical institutions, franchise hospital operations in China's Hainan medical tourism zone, and exclusive distribution partnerships — most notably the BioPlus-Chimin (Haenam) joint venture for all-China distribution. Revenue scaled from 17B KRW in 2019 to 37.4B KRW in 2021 (~$28M USD), and the company has aggressively expanded into biopharmaceuticals through controlling and minority equity stakes in UbiProtein (52.96%, botulinum toxin and GLP-1), Novelgen (5.53%, virus treatments), ProCell Therapeutics (7.3%, next-gen botulinum toxin), and Ora Bio (43.4%, botulinum toxin strain), with a committed 200 billion KRW Seongbon Industrial Complex facility to scale production roughly 10x.

Short descriptiontext

BioPlus Co., Ltd. is a South Korean KOSDAQ-listed biomedical company that develops hyaluronic acid fillers, medical devices, and cosmeceuticals using proprietary MDM® technology and DVS crosslinking. It serves aesthetic clinics and hospitals globally and is expanding into biopharmaceuticals via strategic biotech investments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyaluronic acid fillers, dermal filler manufacturing, medical aesthetic devices, anti-adhesion barriers, cosmeceutical mesotherapy
Industry3 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medical Equipment and Supplies Manufacturing33911
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Perfumes, Cosmetics & Other Toilet Preparations2844
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Aesthetic Medical Devices & Dermal Fillers
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Hyaluronic Acid Fillers
TypeOne Time License
Description

Sales of MDM HA dermal fillers including SkinPlus-Hyal, Bio+ Dew, HyalDew series, DeneB, IPCHE products. Premium DVS-based fillers priced 5x higher than competitors with 48.7% operating profit margin in 2021.

ubioplus.com
2Medical Devices
TypeOne Time License
Description

Medical device products including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), Blad-Care (cystitis treatment). Products approved by various regulatory bodies including UK MHRA.

ubioplus.com
3Cosmeceuticals/Mesotherapy
TypeOne Time License
Description

Cosmeceutical products including Kiara, KiaraReju, KiaraPlus Aura, SlimSlimmer, LumiDew, Labella series for skin rejuvenation, hydration, and aesthetic treatments.

ubioplus.com
4Technology Licensing
TypeLicensing Royalties
Description

Technology transfer of anti-adhesion drugs and other biomaterials to global companies for overseas regions. Joint development agreements with technology partnerships.

ubioplus.com
5Franchise Hospital Operations
TypeProfessional Services
Description

Direct beauty and plastic surgery franchise hospital operations in China through Hainan subsidiary, targeting breast and vaginal plastic surgery markets not allowed in mainland China.

ubioplus.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Premium DVS-based HA fillers priced significantly higher than competitors
ModelUnit PricingBilling cadencePay-as-you-go
Notes

BioPlus supplies products more than five times more expensive than competitors using DVS-based HA fillers. Company achieved 48.7% operating profit margin with premium pricing strategy.

ubioplus.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioPlus manufactures and sells hyaluronic acid-based biomedical products across three categories: (1) MDM® dermal fillers (SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, IPCHE) for aesthetic procedures; (2) medical devices including InterBlock anti-adhesion barrier, HyalSyno synovial fluid replacement, and Blad-Care cystitis treatment; and (3) cosmeceutical/mesotherapy products (Kiara, Labella, Juvenihill). Products are sold to medical professionals and clinics domestically and exported internationally, leveraging proprietary MDM® Technology platform with DVS-based crosslinking.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Operating profit margin of 48.7% in 2021, significantly exceeding competitors in 10-30% range
+2 more records
Product overview1 text field

BioPlus Co., Ltd. is a biomedical device and pharmaceutical company specializing in hyaluronic acid-based products developed through its proprietary MDM® Technology platform. The company operates across three main product categories: (1) MDM Fillers including SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, and IPCHE products for aesthetic applications; (2) Medical devices including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), and Blad-Care (cystitis treatment); and (3) Cosmeceutical mesotherapy products under the Kiara and Labella brands. The MDM Technology platform combines MBMT (Micro Bead Monophasic Technology), DMCT (Divinyl sulfone Multi-Crosslink Technology), and MDAP (Multiple Degree Amphiphilic Purification) to create differentiated hyaluronic acid-based biomaterials with enhanced safety and efficacy.

Product and service2 records
1SkinPlus-Hyal (MDM Filler)
CategoryMDM Dermal Filler
Description

Hyaluronic acid dermal filler utilizing proprietary MDM technology for wrinkle treatment and facial augmentation.

2Bio+ Dew
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development agreement for biocompatible polymer-based drug delivery system to improve stability and sustainability of biopharmaceuticals. Goal is to develop smart nano-medicine combining BioPlus biopharmaceuticals with PHI Biomed's polymer formulation technology. Collaboration in distribution, sale, and commercialization of existing and newly developed products.

2UbiProtein
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioPlus acquired 52.96% stake for 2.625 billion KRW to secure management rights. UbiProtein is a platform company with 22 types of biobetter protein drug patents including AUT (Anti-Ubiquitization Technology) for protein half-life enhancement. Enables development of improved botulinum toxin, GLP-1 obesity/diabetes treatments.

ubioplus.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Business cooperation contract for medical device business in China including hyaluronic acid fillers and agents. Joint venture Bioplus-Chimin (Haenam) Co., Ltd. established for import license and exclusive distribution rights across all China regions. Products include HyalDew filler, InterBlock anti-adhesion, HyalSyno articular lubricant, Blad-Care cystitis treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint development agreement for virus treatments. Noblegen provides NVG308 mini-antibody pipeline effective against COVID-19 and influenza viruses. BioPlus handles substance production, clinical trials, licensing, and sales. Expansion from earlier BioPlus-Noblegen agreement to include nano-sized biopolymer technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

MOU for joint development of virus treatments incorporating nano-sized biopolymer technology from Gachon University as original technology. Development of treatments for COVID-19, AIDS, hepatitis using stabilized antiviral antibodies.

6UROALL (Prof. Park Myung-chan, Inje University)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MOU for joint development of medical device combining BioPlus InterBlock anti-adhesion drug with UROALL's drug-releasing catheter for urethral stenosis prevention and treatment.

ubioplus.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Technology cooperation contract for ubi protein Co., Ltd. to establish foothold for biobetter business development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest pure-play dermatology company and maker of the Restylane HA filler franchise, competing head-to-head with BioPlus in aesthetic HA fillers. Comparable in HA filler technology focus and product positioning, but with established global distribution, broader aesthetics portfolio, and a multi-decade safety database that BioPlus lacks.

TypeDirect peer
Description

European aesthetics company with HA fillers, biostimulators, and thread lifting products, recently acquired by Huadong Medicine. Comparable to BioPlus in premium aesthetics positioning and international expansion ambitions, with a similarly broad product portfolio spanning HA and adjacent aesthetics.

TypeBroad incumbent
Description

Global aesthetics market leader and maker of the Juvederm HA dermal filler franchise, plus Botox. Directly comparable to BioPlus in HA filler category but operates at vastly greater scale, with FDA-cleared products in the US and global commercial reach that BioPlus is still building.

TypeDirect peer
Description

South Korean aesthetics company with Botulax (botulinum toxin) and dermal filler products, listed on KOSDAQ. Direct Korean peer to BioPlus in aesthetics, with similar premium positioning in Korea and overlapping international expansion strategies, but at materially larger scale and with established botulinum toxin leadership.

5LG Chem (LG Life Sciences)
TypeBroad incumbent
Description

Major Korean chemical and life sciences company producing Yvoire HA dermal fillers. Comparable to BioPlus in HA filler technology but embedded in a much larger diversified industrial conglomerate with global distribution and substantially greater R&D resources.

TypeDirect peer
Description

US-based company specializing in HA-based products including joint health (viscosupplementation, comparable to HyalSyno) and regenerative aesthetics. Directly comparable to BioPlus's medical device business (InterBlock, HyalSyno) and provides a public-market comp for the HA platform value of BioPlus.

TypeBroad incumbent
Description

Global aesthetics player selling Belotero HA dermal fillers, Radiesse biostimulator, and Ultherapy. Comparable to BioPlus in the HA filler category but serves a broader aesthetics portfolio and operates at significantly larger scale across all major geographies.

TypeDirect peer
Description

Korean aesthetic biopharmaceutical company developing Neuronox botulinum toxin and HA dermal fillers, KOSDAQ-listed. Most direct Korean comp to BioPlus in combining HA fillers with adjacent biopharma (botulinum toxin) and competing in similar export markets.

TypeDirect peer
Description

Swiss premium HA dermal filler company (Teosyal range) competing in the same premium aesthetic segment as BioPlus. Both companies emphasize proprietary crosslinking technology and premium pricing, making Teoxane one of the closest direct comps to BioPlus's DVS-based positioning, though Teoxane uses traditional BDDE chemistry.

TypeRegional player
Description

Korean pharmaceutical company selling Nabota botulinum toxin and aesthetic products, with a direct interest in the same anti-adhesion and biopharmaceutical adjacencies BioPlus is pursuing. Regional Korean comp with similar product portfolio expansion strategy but with established US FDA approval for Nabota that BioPlus lacks.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioplus Co.

Aesthetic Medical Devices & Dermal Fillersubioplus.com

BioPlus Co., Ltd. is a South Korean KOSDAQ-listed biomedical company that develops hyaluronic acid fillers, medical devices, and cosmeceuticals using proprietary MDM® technology and DVS crosslinking. It serves aesthetic clinics and hospitals globally and is expanding into biopharmaceuticals via strategic biotech investments.

What Bioplus Co. does

BioPlus Co., Ltd. is a South Korea-based biomedical device and biopharmaceutical company founded in 2003 and listed on KOSDAQ (ticker 099430) since September 2021. The company specializes in hyaluronic acid (HA)-based products built on its proprietary MDM® Technology platform, which combines Micro Bead Monophasic Technology (MBMT), Divinyl sulfone Multi-Crosslink Technology (DMCT), and Multiple Degree Amphiphilic Purification (MDAP). BioPlus is the only company globally using DVS rather than BDDE as the cross-linking agent for HA dermal fillers, supporting a premium positioning with products priced approximately 5x above competitors and generating a 48.7% operating margin in 2021.

The company's product portfolio spans three categories: (1) MDM® Filler products including SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, and IPCHE for aesthetic applications; (2) Medical devices including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), and Blad-Care (cystitis treatment); and (3) Cosmeceutical/mesotherapy products under the Kiara and Labella brands. BioPlus derives approximately 85% of revenue from HA fillers and serves medical aesthetic clinics, hospitals, and orthopedic/surgical providers across Korea, China, the U.S., Europe, the Middle East, South Asia, Latin America, and Southeast Asia.

BioPlus operates a sales-led go-to-market with premium pricing, combining direct sales to medical institutions, franchise hospital operations in China's Hainan medical tourism zone, and exclusive distribution partnerships — most notably the BioPlus-Chimin (Haenam) joint venture for all-China distribution. Revenue scaled from 17B KRW in 2019 to 37.4B KRW in 2021 (~$28M USD), and the company has aggressively expanded into biopharmaceuticals through controlling and minority equity stakes in UbiProtein (52.96%, botulinum toxin and GLP-1), Novelgen (5.53%, virus treatments), ProCell Therapeutics (7.3%, next-gen botulinum toxin), and Ora Bio (43.4%, botulinum toxin strain), with a committed 200 billion KRW Seongbon Industrial Complex facility to scale production roughly 10x.

Bioplus Co. firmographics

Firmographics
Name
Bioplus Co.
Legal name
BioPlus Co., Ltd.
Website
https://ubioplus.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
BioPlus Co., Ltd. is a South Korean KOSDAQ-listed biomedical company that develops hyaluronic acid fillers, medical devices, and cosmeceuticals using proprietary MDM® technology and DVS crosslinking. It serves aesthetic clinics and hospitals globally and is expanding into biopharmaceuticals via strategic biotech investments.
Ownership category
akta.pro rank

Bioplus Co. industry classification

Industry
Product category
Aesthetic Medical Devices & Dermal Fillers
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (33911), Surgical and Medical Instrument Manufacturing (339112)
SIC
Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Hyaluronic acid fillers
  • Dermal filler manufacturing
  • Medical aesthetic devices
  • Anti-adhesion barriers
  • Cosmeceutical mesotherapy

Where Bioplus Co. is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices5 records

Markets served

Bioplus Co. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Hyaluronic Acid Fillers: Sales of MDM HA dermal fillers including SkinPlus-Hyal, Bio+ Dew, HyalDew series, DeneB, IPCHE products. Premium DVS-based fillers priced 5x higher than competitors with 48.7% operating profit margin in 2021.
  2. Medical Devices: Medical device products including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), Blad-Care (cystitis treatment). Products approved by various regulatory bodies including UK MHRA.
  3. Cosmeceuticals/Mesotherapy: Cosmeceutical products including Kiara, KiaraReju, KiaraPlus Aura, SlimSlimmer, LumiDew, Labella series for skin rejuvenation, hydration, and aesthetic treatments.
  4. Technology Licensing: Technology transfer of anti-adhesion drugs and other biomaterials to global companies for overseas regions. Joint development agreements with technology partnerships.
  5. Franchise Hospital Operations: Direct beauty and plastic surgery franchise hospital operations in China through Hainan subsidiary, targeting breast and vaginal plastic surgery markets not allowed in mainland China.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPremium DVS-based HA fillers priced significantly higher than competitors

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Bioplus Co. product offering

Product offering

Core offering

BioPlus manufactures and sells hyaluronic acid-based biomedical products across three categories: (1) MDM® dermal fillers (SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, IPCHE) for aesthetic procedures; (2) medical devices including InterBlock anti-adhesion barrier, HyalSyno synovial fluid replacement, and Blad-Care cystitis treatment; and (3) cosmeceutical/mesotherapy products (Kiara, Labella, Juvenihill). Products are sold to medical professionals and clinics domestically and exported internationally, leveraging proprietary MDM® Technology platform with DVS-based crosslinking.

Product overview

BioPlus Co., Ltd. is a biomedical device and pharmaceutical company specializing in hyaluronic acid-based products developed through its proprietary MDM® Technology platform. The company operates across three main product categories: (1) MDM Fillers including SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, and IPCHE products for aesthetic applications; (2) Medical devices including InterBlock (anti-adhesion barrier), HyalSyno (synovial fluid replacement), and Blad-Care (cystitis treatment); and (3) Cosmeceutical mesotherapy products under the Kiara and Labella brands. The MDM Technology platform combines MBMT (Micro Bead Monophasic Technology), DMCT (Divinyl sulfone Multi-Crosslink Technology), and MDAP (Multiple Degree Amphiphilic Purification) to create differentiated hyaluronic acid-based biomaterials with enhanced safety and efficacy.

Differentiator

Problem solved

Functional benefit

Products and services

  • SkinPlus-Hyal (MDM Filler) Hyaluronic acid dermal filler utilizing proprietary MDM technology for wrinkle treatment and facial augmentation.
  • Bio+ Dew

Quantifiable outcome

  • Operating profit margin of 48.7% in 2021, significantly exceeding competitors in 10-30% range
  • +2 more outcomes

Companies that use Bioplus Co.

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Bioplus Co. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Bioplus Co. partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • PHI BIOMEDcoreStrategic or Co-development PartnerCo-development agreement for biocompatible polymer-based drug delivery system to improve stability and sustainability of biopharmaceuticals. Goal is to develop smart nano-medicine combining BioPlus biopharmaceuticals with PHI Biomed's polymer formulation technology. Collaboration in distribution, sale, and commercialization of existing and newly developed products.
  • UbiProteincoreStrategic or Co-development PartnerBioPlus acquired 52.96% stake for 2.625 billion KRW to secure management rights. UbiProtein is a platform company with 22 types of biobetter protein drug patents including AUT (Anti-Ubiquitization Technology) for protein half-life enhancement. Enables development of improved botulinum toxin, GLP-1 obesity/diabetes treatments.
  • Chimin Health ManagementcoreStrategic or Co-development PartnerBusiness cooperation contract for medical device business in China including hyaluronic acid fillers and agents. Joint venture Bioplus-Chimin (Haenam) Co., Ltd. established for import license and exclusive distribution rights across all China regions. Products include HyalDew filler, InterBlock anti-adhesion, HyalSyno articular lubricant, Blad-Care cystitis treatment.
  • NoblegencoreStrategic or Co-development PartnerJoint development agreement for virus treatments. Noblegen provides NVG308 mini-antibody pipeline effective against COVID-19 and influenza viruses. BioPlus handles substance production, clinical trials, licensing, and sales. Expansion from earlier BioPlus-Noblegen agreement to include nano-sized biopolymer technology.
  • Gachon University (Prof. Kim Moon-il, Prof. Kim Il-tae)minorStrategic or Co-development PartnerMOU for joint development of virus treatments incorporating nano-sized biopolymer technology from Gachon University as original technology. Development of treatments for COVID-19, AIDS, hepatitis using stabilized antiviral antibodies.
  • UROALL (Prof. Park Myung-chan, Inje University)minorStrategic or Co-development PartnerMOU for joint development of medical device combining BioPlus InterBlock anti-adhesion drug with UROALL's drug-releasing catheter for urethral stenosis prevention and treatment.
  • Ora BiominorStrategic or Co-development PartnerTechnology cooperation contract for ubi protein Co., Ltd. to establish foothold for biobetter business development.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Bioplus Co. competitors and assessment

Company assessment

Broad incumbents

  • Galderma: World's largest pure-play dermatology company and maker of the Restylane HA filler franchise, competing head-to-head with BioPlus in aesthetic HA fillers. Comparable in HA filler technology focus and product positioning, but with established global distribution, broader aesthetics portfolio, and a multi-decade safety database that BioPlus lacks.
  • Allergan Aesthetics (AbbVie): Global aesthetics market leader and maker of the Juvederm HA dermal filler franchise, plus Botox. Directly comparable to BioPlus in HA filler category but operates at vastly greater scale, with FDA-cleared products in the US and global commercial reach that BioPlus is still building.
  • LG Chem (LG Life Sciences): Major Korean chemical and life sciences company producing Yvoire HA dermal fillers. Comparable to BioPlus in HA filler technology but embedded in a much larger diversified industrial conglomerate with global distribution and substantially greater R&D resources.
  • Merz Aesthetics: Global aesthetics player selling Belotero HA dermal fillers, Radiesse biostimulator, and Ultherapy. Comparable to BioPlus in the HA filler category but serves a broader aesthetics portfolio and operates at significantly larger scale across all major geographies.

Direct peers

  • Sinclair Pharma: European aesthetics company with HA fillers, biostimulators, and thread lifting products, recently acquired by Huadong Medicine. Comparable to BioPlus in premium aesthetics positioning and international expansion ambitions, with a similarly broad product portfolio spanning HA and adjacent aesthetics.
  • Hugel: South Korean aesthetics company with Botulax (botulinum toxin) and dermal filler products, listed on KOSDAQ. Direct Korean peer to BioPlus in aesthetics, with similar premium positioning in Korea and overlapping international expansion strategies, but at materially larger scale and with established botulinum toxin leadership.
  • Anika Therapeutics: US-based company specializing in HA-based products including joint health (viscosupplementation, comparable to HyalSyno) and regenerative aesthetics. Directly comparable to BioPlus's medical device business (InterBlock, HyalSyno) and provides a public-market comp for the HA platform value of BioPlus.
  • Medytox: Korean aesthetic biopharmaceutical company developing Neuronox botulinum toxin and HA dermal fillers, KOSDAQ-listed. Most direct Korean comp to BioPlus in combining HA fillers with adjacent biopharma (botulinum toxin) and competing in similar export markets.
  • Teoxane: Swiss premium HA dermal filler company (Teosyal range) competing in the same premium aesthetic segment as BioPlus. Both companies emphasize proprietary crosslinking technology and premium pricing, making Teoxane one of the closest direct comps to BioPlus's DVS-based positioning, though Teoxane uses traditional BDDE chemistry.

Regional players

  • Daewoong Pharmaceutical: Korean pharmaceutical company selling Nabota botulinum toxin and aesthetic products, with a direct interest in the same anti-adhesion and biopharmaceutical adjacencies BioPlus is pursuing. Regional Korean comp with similar product portfolio expansion strategy but with established US FDA approval for Nabota that BioPlus lacks.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Bioplus Co. social profiles

Digital presence

Bioplus Co. compliance and trust

Trust signal

Compliance5 records

Bioplus Co. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioplus Co. leadership team

Management profile

Number of profiles

Profiles1 record

Bioplus Co. subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Bioplus Co. funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioplus Co. M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioplus Co.

What does Bioplus Co. do?

BioPlus manufactures and sells hyaluronic acid-based biomedical products across three categories: (1) MDM® dermal fillers (SkinPlus-Hyal, Bio+ Dew, HyalDew, DeneB, IPCHE) for aesthetic procedures; (2) medical devices including InterBlock anti-adhesion barrier, HyalSyno synovial fluid replacement, and Blad-Care cystitis treatment; and (3) cosmeceutical/mesotherapy products (Kiara, Labella, Juvenihill). Products are sold to medical professionals and clinics domestically and exported internationally, leveraging proprietary MDM® Technology platform with DVS-based crosslinking.

Is Bioplus Co. a public or private company?

Bioplus Co. is a public company. It is classified as public and is currently operating.

When was Bioplus Co. founded?

Bioplus Co. was founded in 2003. It employs 11 to 50 people.

Where is Bioplus Co. based?

Bioplus Co. is headquartered in Seoul, South Korea, in the Asia region.

How does Bioplus Co. make money?

Five revenue lines are on record. Hyaluronic Acid Fillers are the primary driver. The others are medical Devices, cosmeceuticals/Mesotherapy, technology Licensing and franchise Hospital Operations.

Who are Bioplus Co.'s main competitors?

Broad incumbents on record are Galderma, Allergan Aesthetics (AbbVie), LG Chem (LG Life Sciences) and Merz Aesthetics. Direct peers are Sinclair Pharma, Hugel, Anika Therapeutics, Medytox and Teoxane. Daewoong Pharmaceutical is listed as a regional player.

Does Bioplus Co. have an API?

No public API is recorded for Bioplus Co..

What industry is Bioplus Co. in?

Bioplus Co.'s product category is Aesthetic Medical Devices & Dermal Fillers. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 3254 and its SIC code is 2844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals